Fig. 4: Association of key serum analytes with grade ≥2 CRS or grade ≥2 neurologic events.
The heat map depicts the median fold change of serum cytokine or chemokine levels from baseline over time (regardless of statistical significance). Analytes included are those that were elevated after axi‑cel infusion in >50% of participants, with a >2-fold change in peak level from baseline (magnitude of fold change indicated by purple shading). Median peak serum concentrations and AUC levels significantly associated with grade ≥2 CRS or grade ≥2 neurologic events in ZUMA-1 cohort 1 and ZUMA-14 are indicated with blue or gray boxes, respectively (nominal P < 0.05) and denoted with * (associated with peak levels) or ^ (associated with AUC levels) when association was observed only for one correlate. Peak serum concentration was defined as the maximum value from baseline to day 28. Nominal two-sided P values were calculated from the Wilcoxon rank-sum test, a rank-based nonparametric test for two groups (grade ≥2 versus grade 1 or none). NE, neurologic event.
